|
|
|
In addition to Menveo, Novartis Vaccines is developing a recombinant vaccine for its potential to provide broad coverage against multiple strains of serogroup B, for which no vaccine is currently available.
Five serogroups cause the majority of meningococcal disease worldwide: A, B, C, W-135 and Y[1]. While Asia has primarily seen serogroup A, recent outbreaks of serogroup C have been noted. There can be no guarantee that Menveo will be approved for sale in any market. Novartis Vaccines is the world's fifth-largest vaccines manufacturer and second-largest supplier of flu vaccines in the US. Focused solely on healthcare, Novartis offers a diversified portfolio to best meet these needs: innovative medicines, cost-saving generic pharmaceuticals, preventive vaccines, diagnostic tools and consumer health products. [5. A number of treated animals continued to be monitored until the end of six months and analysis of those animals is currently underway. These include:
-- Flexible Treatment Paradigm AEOL 10150 is intended for the treatment of patients post-exposure, even in those who are already exhibiting symptoms, eliminating the need for immediate administration in a predefined treatment window. This approach has the added benefit of not requiring biodosimetry (a means of laboratory analysis of the blood to determine the level of radiation exposure).
15 mg xanax tid overdose buy xanax online without a prescription discount xanax discount doctor online xanax drug dependence xanax icd-9 free xanax no rx xanax next day delivery snorting xanax effects
Chiron, the blood testing business, is dedicated to preventing the spread of infectious diseases through the development of novel blood-screening tools that protect the world's blood supply.
References [1.05) survival advantage, statistically significant differences in body weights and wet lung weights were seen over the first six weeks of the study. We believe AEOL 10150 could be a compelling countermeasure for Acute Radiation Syndrome (ARS) and are committed to working with our partners at Duke University, the University of Maryland and the National Institutes of Health (NIH) National Institutes of Allergies and Infectious Diseases (NIAID) to accelerate the development and approval of this product with the goal of providing protection against nuclear and radiological threats to the citizens of our country. These include:
-- Flexible Treatment Paradigm AEOL 10150 is intended for the treatment of patients post-exposure, even in those who are already exhibiting symptoms, eliminating the need for immediate administration in a predefined treatment window.
-- Advanced Development Stage AEOL 10150 has demonstrated safety in three human clinical trials, and has an extensive pre-clinical safety and toxicology package completed.
|
|
No News has been posted yet
|
|
|
Forgotten your password? Request a new one here.
|
 Guests Online: 1
No Members Online
Registered Members: 1
Unactivated Members: 0
Newest Member: Owen Electrical
|
|
v6.01.1 © 2003-2005